Neurocrine biosciences presents breadth of data demonstrating holistic improvements over time in patients with tardive dyskinesia following treatment with ingrezza® (valbenazine) capsules

Findings presented at the 2024 psych congress include data from more than 300 patients san diego , nov. 4, 2024 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) presented data from more than 300 patients diagnosed with tardive dyskinesia and treated with ingrezza® (valbenazine) capsules. these data showed significant improvements in functional, social, emotional and health-related quality of life measures in phase 3 and 4 studies and improvements in functional, social, independence, emotional and physical aspects of patients' lives and antipsychotic adherence in real-world practice.
NBIX Ratings Summary
NBIX Quant Ranking